



News Release

Ashland showcases oral biologics excipient permexa™ sodium caprate and expanded injectables portfolio at October industry events

Company to highlight details during CPHI and AAPS 2026 tradeshow

WILMINGTON, Del., October 1, 2026 – Ashland is spotlighting several new and expanded pharmaceutical solutions during CPHI Milan, October 6-8 (booth 1B42) and at AAPS PharmSci 360, New Orleans, LA, October 25-28, 2026 (booth 925). This includes recently launched **permexa™ sodium caprate**, a novel permeation enhancer designed to support the oral delivery of biologics, peptides, GLP-1 therapies and other poorly permeable molecules. Permexa™ sodium caprate recently gained industry recognition as a finalist for the CPHI Pharma Awards 2026 in the Finished Formulation category, highlighting its potential to advance oral biologics development and pharmaceutical manufacturing performance.

During the shows Ashland will also emphasize the expansion of its injectables platform through its growing family of vialose™ High Purity Low Endotoxin (HPLE) sugars, including **vialose™ mannitol** slated for a November 2026 commercial launch.

With permexa™ sodium caprate, Ashland is supporting the pharmaceutical industry's growing focus on oral biologics and peptide therapeutics to address both permeation and manufacturability challenges in oral solid dosage formulations. Unlike conventional sodium caprate materials, permexa™ provides improved powder flow, compactibility and handling characteristics, enabling more robust tablet production while maintaining the permeation enhancement performance required for next-generation oral therapies.

"Oral delivery continues to represent one of the most exciting opportunities in pharmaceutical development, particularly for biologics, peptide therapeutics and GLP-1 medicines," said Caroline Cooreman, senior director, strategy and business development, Life Sciences, Ashland. "Permexa™ sodium caprate was specifically designed to help address one of the key challenges associated with oral biologics development by combining permeation enhancement with improved manufacturability. Together with our expanding portfolio of supporting excipients, it reflects the Ashland commitment to enabling the next generation of patient-friendly therapies."

Within their excipient portfolio, Ashland offers a broad range of oral solid dosage, injectable and drug delivery solutions that help improve pharmaceutical formulation performance and patient outcomes. The company continues to expand its injectable excipient platform through the growing family of vialose™ highly purified sugars, including trehalose dihydrate, sucrose and the upcoming release of **vialose™ mannitol**. These HPLE excipients are commonly used in biological medicines as protein stabilizers and lyoprotectants in applications including monoclonal antibodies, vaccines, peptides and advanced therapeutics.

Ashland also offers a comprehensive portfolio of solutions supporting injectable, implantable and advanced drug delivery applications, including viatel™ bioresorbable polymers, cyclodextrins and specialty excipients designed to address evolving pharmaceutical formulation challenges.

"As biologics and advanced therapeutics continue to reshape the pharmaceutical landscape, excipient performance, reliability and supply assurance have become increasingly important," said Alessandra Faccin Assis, senior vice president and general manager, Life Sciences and Intermediates, Ashland. "With innovations like permexa™ sodium caprate and the continued expansion of our vialose™ highly purified sugars portfolio, Ashland is helping customers address formulation challenges across both oral and injectable drug delivery platforms."

Ashland combines innovative excipients with deep formulation expertise to help pharmaceutical companies accelerate the development and commercialization of patient-centric medicines. To learn more or request a meeting during the tradeshow, visit the [CPHI overview](#) or the [AAPS overview](#) or connect with an Ashland solver at CPHI Milan (booth 1B42) or AAPS PharmSci 360 (booth 925) this October. For more information about [permexa™ sodium caprate](#), [vialose™ highly purified sugars](#), [viatel™ bioresorbable polymers](#) and Ashland's broader [pharmaceutical excipient portfolio](#), contact your local Ashland solver.

About Ashland

Ashland Inc. (NYSE: ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, personal care and pharmaceutical. Approximately 2,960 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit [ashland.com](#) and [ashland.com/ESG](#) to learn more.

™ Trademark, Ashland or its subsidiaries, registered in various countries.

Media Relations:

Global

Alissa Bye

alissa.bye@ashland.com

EMEA

Sandra Carstens

Add email

sandra.carstens@ashland.com